Global Nano-drug Market Insights, Research Forecast to 2025

Published On: Sep 2019

Format: PDF

Publisher: QY Research

Pages: 121

Report ID: 60544

The global Nano-drug market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Nano-drug market based on company, product type, end user and key regions.

This report studies the global market size of Nano-drug in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Nano-drug in these regions.
This research report categorizes the global Nano-drug market by top players/brands, region, type and end user. This report also studies the global Nano-drug market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Eli Lilly
Johnson & Johnson
Gilead Sciences
OSI Pharmaceuticals
Kadmon Pharmaceuticals
Samyang Biopharm
Mitsubishi Pharma
Kaken Pharmaceutical
Selecta Biosciences
Par Pharmaceutical
Cerulean Pharma
Navidea Biopharmaceuticals

Market size by Product
Polymeric Micelles
Solid lipid Nanoparticles
Microemulsion and Nanoemulsion
Market size by End User
Cancer and Tumors
Autoimmune Disorders

Market size by Region
North America
United States
South Korea
Central & South America
Rest of Central & South America
Middle East & Africa
GCC Countries
South Africa

The study objectives of this report are:
To study and analyze the global Nano-drug market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Nano-drug market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Nano-drug companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Nano-drug submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Nano-drug are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Doses). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Nano-drug market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Study Coverage
1.1 Nano-drug Product
1.2 Market Segments
1.3 Key Manufacturers Covered
1.4 Market by Type
1.4.1 Global Nano-drug Market Size Growth Rate by Product
1.4.2 Liposomes
1.4.3 Polymeric Micelles
1.4.4 Solid lipid Nanoparticles
1.4.5 Microemulsion and Nanoemulsion
1.4.6 Nanosuspension
1.5 Market by End User
1.5.1 Global Nano-drug Market Size Growth Rate by End User
1.5.2 Cancer and Tumors
1.5.3 Autoimmune Disorders
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Nano-drug Market Size
2.1.1 Global Nano-drug Revenue 2014-2025
2.1.2 Global Nano-drug Sales 2014-2025
2.2 Nano-drug Growth Rate by Regions
2.2.1 Global Nano-drug Sales by Regions
2.2.2 Global Nano-drug Revenue by Regions

3 Breakdown Data by Manufacturers
3.1 Nano-drug Sales by Manufacturers
3.1.1 Nano-drug Sales by Manufacturers
3.1.2 Nano-drug Sales Market Share by Manufacturers
3.1.3 Global Nano-drug Market Concentration Ratio (CR5 and HHI)
3.2 Nano-drug Revenue by Manufacturers
3.2.1 Nano-drug Revenue by Manufacturers (2014-2019)
3.2.2 Nano-drug Revenue Share by Manufacturers (2014-2019)
3.3 Nano-drug Price by Manufacturers
3.4 Nano-drug Manufacturing Base Distribution, Product Types
3.4.1 Nano-drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Nano-drug Product Type
3.4.3 Date of International Manufacturers Enter into Nano-drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product
4.1 Global Nano-drug Sales by Product
4.2 Global Nano-drug Revenue by Product
4.3 Nano-drug Price by Product

5 Breakdown Data by End User
5.1 Overview
5.2 Global Nano-drug Breakdown Data by End User

6 North America
6.1 North America Nano-drug by Countries
6.1.1 North America Nano-drug Sales by Countries
6.1.2 North America Nano-drug Revenue by Countries
6.1.3 United States
6.1.4 Canada
6.1.5 Mexico
6.2 North America Nano-drug by Product
6.3 North America Nano-drug by End User

7 Europe
7.1 Europe Nano-drug by Countries
7.1.1 Europe Nano-drug Sales by Countries
7.1.2 Europe Nano-drug Revenue by Countries
7.1.3 Germany
7.1.4 France
7.1.5 UK
7.1.6 Italy
7.1.7 Russia
7.2 Europe Nano-drug by Product
7.3 Europe Nano-drug by End User

8 Asia Pacific
8.1 Asia Pacific Nano-drug by Countries
8.1.1 Asia Pacific Nano-drug Sales by Countries
8.1.2 Asia Pacific Nano-drug Revenue by Countries
8.1.3 China
8.1.4 Japan
8.1.5 Korea
8.1.6 India
8.1.7 Australia
8.1.8 Indonesia
8.1.9 Malaysia
8.1.10 Philippines
8.1.11 Thailand
8.1.12 Vietnam
8.1.13 Singapore
8.2 Asia Pacific Nano-drug by Product
8.3 Asia Pacific Nano-drug by End User

9 Central & South America
9.1 Central & South America Nano-drug by Countries
9.1.1 Central & South America Nano-drug Sales by Countries
9.1.2 Central & South America Nano-drug Revenue by Countries
9.1.3 Brazil
9.2 Central & South America Nano-drug by Product
9.3 Central & South America Nano-drug by End User

10 Middle East and Africa
10.1 Middle East and Africa Nano-drug by Countries
10.1.1 Middle East and Africa Nano-drug Sales by Countries
10.1.2 Middle East and Africa Nano-drug Revenue by Countries
10.1.3 GCC Countries
10.1.4 Turkey
10.1.5 Egypt
10.1.6 South Africa
10.2 Middle East and Africa Nano-drug by Product
10.3 Middle East and Africa Nano-drug by End User

11 Company Profiles
11.1 Merck
11.1.1 Merck Company Details
11.1.2 Company Business Overview
11.1.3 Merck Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.1.4 Merck Nano-drug Products Offered
11.1.5 Merck Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Company Business Overview
11.2.3 Pfizer Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.2.4 Pfizer Nano-drug Products Offered
11.2.5 Pfizer Recent Development
11.3 Novartis
11.3.1 Novartis Company Details
11.3.2 Company Business Overview
11.3.3 Novartis Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.3.4 Novartis Nano-drug Products Offered
11.3.5 Novartis Recent Development
11.4 Abbott
11.4.1 Abbott Company Details
11.4.2 Company Business Overview
11.4.3 Abbott Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.4.4 Abbott Nano-drug Products Offered
11.4.5 Abbott Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Details
11.5.2 Company Business Overview
11.5.3 GlaxoSmithKline Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.5.4 GlaxoSmithKline Nano-drug Products Offered
11.5.5 GlaxoSmithKline Recent Development
11.6 Roche
11.6.1 Roche Company Details
11.6.2 Company Business Overview
11.6.3 Roche Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.6.4 Roche Nano-drug Products Offered
11.6.5 Roche Recent Development
11.7 Sanofi
11.7.1 Sanofi Company Details
11.7.2 Company Business Overview
11.7.3 Sanofi Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.7.4 Sanofi Nano-drug Products Offered
11.7.5 Sanofi Recent Development
11.8 Eli Lilly
11.8.1 Eli Lilly Company Details
11.8.2 Company Business Overview
11.8.3 Eli Lilly Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.8.4 Eli Lilly Nano-drug Products Offered
11.8.5 Eli Lilly Recent Development
11.9 Astrazeneca
11.9.1 Astrazeneca Company Details
11.9.2 Company Business Overview
11.9.3 Astrazeneca Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.9.4 Astrazeneca Nano-drug Products Offered
11.9.5 Astrazeneca Recent Development
11.10 Johnson & Johnson
11.10.1 Johnson & Johnson Company Details
11.10.2 Company Business Overview
11.10.3 Johnson & Johnson Nano-drug Sales, Revenue and Gross Margin (2014-2019)
11.10.4 Johnson & Johnson Nano-drug Products Offered
11.10.5 Johnson & Johnson Recent Development
11.11 Celgene
11.12 Novavax
11.13 Stryker
11.14 Gilead Sciences
11.15 OSI Pharmaceuticals
11.16 Kadmon Pharmaceuticals
11.17 Samyang Biopharm
11.18 Mitsubishi Pharma
11.19 Kaken Pharmaceutical
11.20 Selecta Biosciences
11.21 Par Pharmaceutical
11.22 Cerulean Pharma
11.23 Navidea Biopharmaceuticals
11.24 Lummy

12 Future Forecast
12.1 Nano-drug Market Forecast by Regions
12.1.1 Global Nano-drug Sales Forecast by Regions 2019-2025
12.1.2 Global Nano-drug Revenue Forecast by Regions 2019-2025
12.2 Nano-drug Market Forecast by Product
12.2.1 Global Nano-drug Sales Forecast by Product 2019-2025
12.2.2 Global Nano-drug Revenue Forecast by Product 2019-2025
12.3 Nano-drug Market Forecast by End User
12.4 North America Nano-drug Forecast
12.5 Europe Nano-drug Forecast
12.6 Asia Pacific Nano-drug Forecast
12.7 Central & South America Nano-drug Forecast
12.8 Middle East and Africa Nano-drug Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Nano-drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer